Frontiers in Pharmacology (Dec 2023)

PdMo nanoflowers for endogenous/exogenous-stimulated nanocatalytic therapy

  • Xinqiang Liang,
  • Yanping Tang,
  • Mekhrdod S. Kurboniyon,
  • Danni Luo,
  • Guiwan Tu,
  • Pengle Xia,
  • Shufang Ning,
  • Litu Zhang,
  • Chen Wang

DOI
https://doi.org/10.3389/fphar.2023.1324764
Journal volume & issue
Vol. 14

Abstract

Read online

The clinical application of reactive oxygen species (ROS)-mediated tumor treatment has been critically limited by inefficient ROS generation. Herein, we rationally synthesized and constructed the three-dimensional PdMo nanoflowers through a one-pot solvothermal reduction method for elaborately regulated peroxidase-like enzymatic activity and glutathione peroxidase-like enzymatic activity, to promote oxidation ROS evolvement and antioxidation glutathione depletion for achieving intensive ROS-mediated tumor therapy. The three-dimensional superstructure composed of two-dimensional nanosheet subunits can solve the issues by avoiding the appearance of tightly stacked crystalline nanostructures. Significantly, Mo is chosen as a second metal to alloy with Pd because of its more chemical valence and negative ionization energy than Pd for improved electron transfer efficiencies and enhanced enzyme-like activities. In addition, the photothermal effect generated by PdMo nanoflowers could also enhance its enzymatic activities. Thus, this work provides a promising paradigm for achieving highly ROS-mediated tumor therapeutic efficacy by regulating the multi-enzymatic activities of Pd-based nanoalloys.

Keywords